Tuesday, February 27, 2024
Oncoteq is a clinical stage oncology biotech with a focus on first or best-in-class treatments in areas of high unmet need. The company portfolio comprises two highly differentiated assets. TEQ103 has a novel model of action selectively killing ERa+ tumor cells and a potential paradigm shift for patients with hormone receptor positive breast cancers. The second asset, a CD30 directed ADC with an innovative hydrophilic linker is a potential best-in-class treatment for CD30 positive cancers. Both assets are set to enter the clinic in the first half of 2025.
CEO/Top Company Official
Lead Product in Development
TEQ102 is a potential best in class ADC against CD30 expressing lymphomas. The ADC utilizes a novel and innovative linker technology with preclinical data to support the potential to deliver improved efficacy with better safety and tolerability to patients and thus enabling patients to stay on treatment longer. TEQ102 is IND ready with solid GLP tox data.
Development Phase of Primary Product